Form 4: IRADIMED CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

IRADIMED's CEO, President, and Chairman, Roger E. Susi, sold common stock totaling 7,500 shares on March 30, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Roger E. Susi, the CEO, President, Chairman, Director, and 10% Owner of IRADIMED CORP (IRMD), reported sales of common stock.
• A total of 7,500 shares of common stock were disposed of on March 30, 2026.
• The sales were executed in three separate transactions at weighted average prices of $94.81, $95.66, and $96.53 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Susi on November 5, 2025.
• Following these transactions, Mr. Susi's indirect beneficial ownership includes 2,225,000 shares held by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust.
• Mr. Susi disclaims beneficial ownership of the securities held by the Matthew Susi 2008 Dynasty Trust except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. Sales under a pre-arranged 10b5-1 plan are typically for personal financial planning and do not inherently signal a change in the insider's outlook on the company's future.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales conducted under a Rule 10b5-1 trading plan are pre-scheduled and designed to allow insiders to sell shares without being accused of trading on material non-public information. Such sales are generally viewed as less indicative of management's immediate sentiment about the company's prospects compared to unscheduled open market sales.

Related Party Transactions

• Roger E. Susi, the CEO, President, Chairman, and Director, executed sales of common stock.
• Beneficial ownership is held indirectly through the Phillip Susi 2008 Dynasty Trust, Roger E. Susi Revocable Trust, and Matthew Susi 2008 Dynasty Trust, indicating transactions and holdings involving related parties.

Stakeholder Impact

• Shareholders may observe a slight increase in the float of shares available in the market due to the sale, though the impact is likely minimal given the pre-planned nature of the transaction.
• The pre-arranged nature of the sale under a 10b5-1 plan generally mitigates concerns among investors about management's confidence in the company's future.

Key Dates

Keywords

IRADIMED, IRMD, Form 4, Insider Transaction, Stock Sale, 10b5-1 Plan, Roger E. Susi, Corporate Governance